Platelet inhibitors and bleeding in cardiac surgical patients.
A variety of measures may affect bleeding and transfusion requirements in abciximab-treated patients. These measures include recognition of the risk factors for increased bleeding and transfusion requirements, use of proper transfusion practices, conservation or increasing of red cell mass, appropriate heparin dosing and protamine reversal, reversal of anticoagulation, awareness of factors that affect activated clotting time (ACT), and appropriate anticoagulation for cardiopulmonary bypass.
Levy
J H
JH
Department of Anesthesiology, Emory University School of Medicine, and Division of Cardiothoracic Anesthesiology, Emory Healthcare, Atlanta, Georgia 30322, USA. jerrold_levy@emory.org
D001780:Blood Coagulation Tests; D001803:Blood Transfusion; D006328:Cardiac Catheterization; D006348:Cardiac Surgical Procedures; D002315:Cardiopulmonary Bypass; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D019106:Postoperative Hemorrhage / Q000503:physiopathology / Q000517:prevention & control*
D010975:Platelet Aggregation Inhibitors